Crisaborole
- Generic Name
- Crisaborole
- Brand Names
- Eucrisa
- Drug Type
- Small Molecule
- Chemical Formula
- C14H10BNO3
- CAS Number
- 906673-24-3
- Unique Ingredient Identifier
- Q2R47HGR7P
- Background
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile. Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme. It is currently under development as topical treatment of psoriasis.
- Indication
Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.
- Associated Conditions
- Mild Atopic dermatitis, Moderate Atopic dermatitis
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 237
- Registration Number
- NCT03539601
- Locations
- 🇺🇸
Arlington Research Center, Inc., Arlington, Texas, United States
🇩🇪Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Schleswig-holstein, Germany
🇵🇱Barbara Rewerska Diamond Clinic, Krakow, Malopolska, Poland
A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 137
- Registration Number
- NCT03356977
- Locations
- 🇺🇸
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Baumann Cosmetic and Research Institute, Miami, Florida, United States
🇺🇸Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Duke University
- Target Recruit Count
- 8
- Registration Number
- NCT03351114
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis
- Conditions
- Atopic DermatitisHealthy
- Interventions
- Drug: Vehicle
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT03260595
- Locations
- 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
Eucrisa for Atopic Dermatitis
- Conditions
- Mild to Moderate Atopic Dermatitis
- Interventions
- Behavioral: Online Treatment response
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT03250663
- Locations
- 🇺🇸
Wake Forest University Heath Sciences, Winston-Salem, North Carolina, United States
Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: Placebo ointment (vehicle)
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT03233529
- Locations
- 🇨🇦
Innovaderm Research Incorporated, Montreal, Quebec, Canada
Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 145
- Registration Number
- NCT01029405
Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT00759161
- Locations
- 🇲🇽
IMIC, Mexico City, Distrito Federal, Mexico
Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00755196
- Locations
- 🇲🇽
IMIC, Mexico City, Distrito Federal, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.